Nivolumab+Sitravati...
 
Notifications
Clear all

Nivolumab+Sitravatinib Combo in clear cell renal cell carcinoma

1 Posts
1 Users
0 Likes
510 Views
johan
(@j)
Joined: 4 years ago
Posts: 1190
Topic starter  

Combining a broad-spectrum tyrosine kinase inhibitor (TKI) with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma:

https://www.kcuk.org.uk/nivolumabsitravatinib-combo-impresses-in-rcc/


   
Quote
Share: